Open Innovation

Let’s bring great ideas to life

Share our passion for new paths in life sciences. Join us in Open Innovation.
OUR COMMITMENT

What's new in Open Innovation

License agreement with Yara

February 20, 2017

Bayer and Yara International ASA (Yara) have entered into a software collaboration and technology license agreement to provide farmers worldwide with digital farming tools that help increase farm productivity, profitability and sustainability.

Stay tuned on Open Innovation

Keep updated with our latest news.

Innovation Stories

Innovation Stories

  • During clinical testing, more than 90 percent of new approaches are rejected, but if one new drug can save lives, then all the work will have been worthwhile.
    Anette Sommer, Principal Scientist in Oncology Research at Bayer AG
    Read the full story
  • Bayer’s researchers have new ideas for developing active medications and clinician researchers like us can screen and select patients based on these ideas who may benefit.
    Prof. Boon Cher Goh, National University Cancer Institute of Singapore
    Read the full story
  • The ‘Grants4Apps Accelerator’ gives innovators a chance to learn and fine-tune everything it takes to successfully market their ideas.
    Jesus del Valle Rosales, Intrapreneurship & Innovation, Bayer Business Services
    Read the full story
  • A growing and aging world population, limited natural resources and the impact of climate change make it important to improve crop yield, stress tolerance and nutritional value while minimizing environmental impact.
    Arjen J. van Tunen, CEO KeyGene
    Read the full story
  • We thought we had a mature understanding of our business model – and emerged with a model that is actually viable for a startup company.
    Robert Green, co-founder Vitameter
    Read the full story
  • I expect immunoncology to become established as an integral part of cancer treatment over the next few years and to offer real prospects.
    Professor Rienk Offringa, Head of the Bayer-DKFZ Joint Lab
    Read the full story
  • Startups whose work is related to Bayer’s pharmaceutical R&D focus are offered rental office and lab space on the company’s campus in Berlin. Working side by side has inspired fruitful scientific discussion.
    Stefan Jaroch, Drug Discovery, Global External Innovation & Alliances, Bayer Pharmaceuticals division
    Read the full story

OPEN INNOVATION IN NUMBERS

Our scientific successes are intended to help improve people’s lives.
At the same time, our innovations form the basis for sustainable and profitable business activity.

0
IDEAS
0
COUNTRIES
0
PROJECTS FUNDED
0
EMPLOYEES
OPEN INNOVATION
IN NUMBERS
3,575 IDEAS
have been submitted to Bayer Open Innovation programs since 2009.
60 COUNTRIES
innovative solutions have been submitted from more than 60 countries worldwide.
285 PROJECTS FUNDED
more than 285 ideas have been supported through Open Innovation Grants from Bayer.
14,026 EMPLOYEES
over 14,000 Bayer employees currently work in R&D.
OPEN INNOVATION
IN NUMBERS
3,575 IDEAS
have been submitted to Bayer Open Innovation programs since 2009.
60 COUNTRIES
innovative solutions have been submitted from more than 60 countries worldwide.
285 PROJECTS FUNDED
more than 285 ideas have been supported through Open Innovation Grants from Bayer.
14,026 EMPLOYEES
over 14,000 Bayer employees currently work in R&D.